Every baby in the UK will have their DNA tested under a new 10-year plan for the NHS. The whole-genome sequencing will screen for hundreds of diseases and allow people to "leapfrog" killer illnesses, ...

Nucleus Genomics has been courting controversy for years with products that claim to tell people how their genetics correlate to a host of complex issues, including their IQ.

Discover how genomics is transforming rare disease diagnosis with advanced genetic testing, providing earlier and more precise diagnoses.

Leading Genomics Information Company brings new innovation to genomics interpretation and consultation, in its mission to enhance the utility of the genome Dante Labs AI (Graphic: Business Wire) ...

DNA analysis is predicting the likelihood of age-related conditions such as heart disease and cancer.

Genomics company 10x and Harvard University have agreed to resolve a patent lawsuit against 10x's rival Vizgen four days into a scheduled two-week trial, according to a Thursday filing in Delaware ...

China offered multiple countries help with covid-19 testing during the pandemic. The payoff for Beijing included access to the DNA of millions of people.

Post this These strategic hires will further enable Arima Genomics to accelerate adoption of its 3D genomics platform, forge innovative partnerships, and expand research and clinical applications.

Genomics study shows early Asians traveled over 20,000 km from North Asia to South America by Nanyang Technological University Editors' notes ...

Singular Genomics Systems, Inc. has announced a definitive merger agreement in which an affiliate of Deerfield Management Company will acquire the company for $20.00 per share, a 254% premium over ...

Illumina will offer its DRAGEN analysis software on Nvidia’s accelerated computing platforms through the next-gen sequencing giant’s Illumina Connected Analytics (ICA) platform.

Biotechnology company 10x Genomics and Harvard University reached a Feb. 6 settlement in a patent lawsuit that they jointly filed against Vizgen Inc. in 2022.